Pharma

Following Intellectual Passions, With Dr. Baruch Kupperman

By Jackie Wengrod | September 29, 2021

PODCAST EPISODE 299

Read More

Despite Mixed Trial Results and Stock Plunge, Apellis Keeps Commitment to Lead Candidate Pegcetacoplan

By Rich Kirkner | September 15, 2021

Despite a sharp dive in its stock price a day after reporting mixed topline results from two Phase III clinical trials of its lead candidate…

Read More

From Big Pharma Lawyer to Eye Care Disruptor: IACTA Pharmaceuticals Founder & CEO Damon Burrows

By Jackie Wengrod | September 15, 2021

PODCAST EPISODE 297 Click here to watch the video version of this podcast. Damon Burrows isn’t a scientist. And he didn’t start IACTA Pharmaceuticals, an…

Read More

NIH Awards Amydis $3 Million Grant Award for Novel Amyloid Beta Retinal Tracer Applicable to CNS Diseases

By Conni Bergmann Koury | August 10, 2021

Amydis is developing novel small-molecule contrast agents that aim to enable the direct visualization of central nervous system (CNS) disease-related biomarkers in the retina. The…

Read More

Stem Cell-Engineered Implant for Geographic Atrophy Shows Promise, Long-Term Survival of Cells in Early Trial

By Conni Bergmann Koury | August 3, 2021

A number of companies are developing drug treatments for geographic atrophy, the result of advanced dry age-related macular degeneration (AMD), for which no approved treatments…

Read More

Apellis Building on Its Platform with APL-2 for Geographic Atrophy

By Steve Lenier | June 8, 2021

Weeks after receiving Food and Drug Administration approval for its complement factor 3 (C3) inhibitor pegcetacoplan, now known as Empaveli, to treat adults who have…

Read More

The Four Trends Driving the Digital Space

By Rich Kirkner | May 25, 2021

Money is pouring into digital health at a record clip – $6.7 billion in the first quarter this year, the investment firm Rock Health reports.…

Read More

Innovega is Moving Quickly in Augmented- and Virtual-Reality Space

By Steve Lenier | May 19, 2021

In 2020 Innovega, which is headquartered in Bellevue, WA, and has development facilities in San Diego, was recognized in a listing of “Cool Companies” selected…

Read More

Novartis-Regeneron Dispute Enters a New Phase

By Rich Kirkner | May 11, 2021

If you can’t beat ‘em, try to beat ‘em another way. On the same day the US International Trade Commission (US ITC) dropped a patent…

Read More

Despite Interruption, Pixium Vision Aims to Keep Moving Toward Commercializing Prima System

By Steve Lenier | April 28, 2021

Despite a potential business arrangement with a fellow retinal prosthesis innovator falling apart in recent weeks, Paris-based Pixium Vision is working to stay on course…

Read More

Gyroscope Therapeutics Completes Financing to Advance Gene Therapy Candidate for GA

By Steve Lenier | April 20, 2021

Gyroscope Therapeutics recently raised $148 million in a Series C financing to advance the clinical development of GT005, its lead investigational gene therapy, which is…

Read More

Anterior Segment Advances That ‘Won’ 2020 and Those Poised To Disrupt the Future

By Conni Bergmann Koury | April 14, 2021

2020 was a challenging year for ophthalmic surgeons, but an array of device and pharma developments helped them get through it, while other advances are…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.